山东第一医科大学附属中心医院(济南市中心医院)
Central Hospital Affiliated to Shandong First Medical University
在本站收录的 61 种疾病中,这家医院列在其中 11 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。
这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。
这家医院的官网还没有核对。
山东第一医科大学附属中心医院(济南市中心医院)的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 61 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 食管鳞状细胞癌Oesophageal squamous cell carcinoma4 篇牵头论文
- 胃癌Stomach cancer31 篇牵头论文
- 肺癌Lung cancer59 篇牵头论文
- 乳腺癌Breast cancer21 篇牵头论文牵头 1 项开放试验
- 视网膜母细胞瘤Retinoblastoma0 篇牵头论文
- 骨肉瘤Osteosarcoma6 篇牵头论文
- 胃肠道间质瘤Gastrointestinal stromal tumour0 篇牵头论文
- 血友病 AHaemophilia A1 篇牵头论文
- 冠心病Coronary heart disease6 篇牵头论文
- 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis2 篇牵头论文
- 家族性腺瘤性息肉病Familial adenomatous polyposis0 篇牵头论文
未列出的收录疾病:鼻咽癌、肝细胞癌、胰腺癌、胶质瘤、肝母细胞瘤、脊索瘤、神经母细胞瘤、尤文肉瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、淋巴瘤、β 地中海贫血、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、先天性心脏病、脊柱侧弯、大动脉炎、肝包虫病、特发性肺纤维化、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、IgA 肾病、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
济南有 6 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
- 分期
- I/II期
- 开始
- 2026-03
- 发布
- 登记号
- NCT07405151
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 7 家列出的医院为研究中心北京、厦门、合肥、徐州、杭州、济南、郑州
- 正在招募A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- 分期
- III期
- 开始
- 2025-03
- 发布
- 登记号
- NCT06644781
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 28 家列出的医院为研究中心临沂、北京、南宁、厦门、合肥、哈尔滨、天津、安阳、成都、扬州、新乡、杭州、武汉、汕头、沈阳、洛阳、济南、济宁、福州、郑州、长春
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文4
- High MRPL12 expression drives esophageal cancer proliferation, invasion and migration.
- Concurrent chemoradiotherapyof different radiation doses and different irradiation fields for locally advanced thoracic esophageal squamous cell carcinoma: A randomized, multicenter, phase III clinical trial.
- Circ_0006948 Contributes to Cell Growth, Migration, Invasion and Epithelial-Mesenchymal Transition in Esophageal Carcinoma.
- MicroRNA-210 targets FBXO31 to inhibit tumor progression and regulates the Wnt/β-catenin signaling pathway and EMT in esophageal squamous cell carcinoma.
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
- A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
- A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).
- A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma
PubMed 以外找到的论文(未计入)5
- 103P Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study
- 1426P BL-B01D1, an EGFR x her3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)
- Updated results of first-line serplulimab versus placebo plus chemotherapy in PD-L1–positive esophageal squamous cell carcinoma: A randomized, double-blind, multicenter phase 3 study (ASTRUM-007).
- Concurrent Chemoradiation of Different Doses (50.4 Gy vs. 59.4 Gy) and Different Target Field (ENI vs. IFI) for Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Randomized, Multicenter Phase Ⅲ Clinical Trial
- Downregulation of long noncoding RNA breast cancer anti-estrogen resistance 4 inhibits cell proliferation, invasion, and migration in esophageal squamous cell carcinoma by regulating the microRNA-181c-5p/LIM and SH3 protein 1 axis
癌症
胃癌
Stomach cancer2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 31 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
济南有 7 家医院列在胃癌下全国有 211 家医院列在胃癌下
这家医院参与的开放试验 3
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- 分期
- III期
- 开始
- 2026-04
- 发布
- 登记号
- NCT07385703
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 64 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛
- 正在招募A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- 分期
- I/II期
- 开始
- 2022-01
- 发布
- 登记号
- NCT05150691
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、北京、南宁、厦门、合肥、天津、安阳、广州、徐州、无锡、杭州、武汉、沈阳、济南、温州、烟台、石家庄、蚌埠、西安、郑州、重庆、长春、长沙
- 正在招募A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
- 分期
- I期
- 开始
- 2022-02
- 发布
- 登记号
- NCT05262491
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 6 家列出的医院为研究中心北京、南昌、天津、成都、杭州、济南
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文31
- MTF1 attenuates ferroptosis and cuproptosis synergistic potentiation in gastric cancer.
- DKN-01 Suppresses Gastric Cancer Progression Through Activating cGAS-STING Pathway to Block Macrophage M2 Polarization.
- Helicobacter pylori-induced aberrant methylation of ID4 mediated by DNMT3B drives gastric cancer progression via DEC1-SHH signaling pathway.
- GLI2 inhibits cisplatin sensitivity in gastric cancer through DEC1/ZEB1 mediated EMT.
- Sanguinarine Inhibits Gastric Cancer Progression by Targeting the NOS2/SOD1 Axis to Promote Ferroptosis.
- Helicobacter pylori infection induces STAT3/MYBL2/NF-κB axis to promote gastric cancer progression.
- A Novel Signature Based on m6A Regulator-Mediated Genes Along Glycolytic Pathway Predicts Prognosis and Immunotherapy Responses of Gastric Cancer Patients.
- Fabrication of Nickel/Zinc Oxide Nanocomposites from Citrus sinensis Extract Prompts Apoptosis Through Impeding JAK/STAT3 Signaling in Gastric Cancer.
- Effect of Intensive Nursing Management on Quality of Life and Mental Health in Elderly Gastric Cancer Patients Undergoing Chemotherapy: A Retrospective Study.
- Positive GLI1/INHBA feedback loop drives tumor progression in gastric cancer.
- Myricetin Induces Ferroptosis and Inhibits Gastric Cancer Progression by Targeting NOX4.
- ROR2 promotes cell cycle progression and cell proliferation through the PI3K/AKT signaling pathway in gastric cancer.
- PKP2 induced by YAP/TEAD4 promotes malignant progression of gastric cancer.
- Virulence gene polymorphisms in Shandong Helicobacter pylori strains and their relevance to gastric cancer.
- Amino acid deletions at positions 893 and 894 of cytotoxin-associated gene A protein affect Helicobacter pylori gastric epithelial cell interactions.
- PHKG2 regulates RSL3-induced ferroptosis in Helicobacter pylori related gastric cancer.
- Helicobacter pylori-induced aberrant demethylation and expression of GNB4 promotes gastric carcinogenesis via the Hippo-YAP1 pathway.
- Targeting Hippo pathway: A novel strategy for Helicobacter pylori-induced gastric cancer treatment.
- SUMOylation of TUFT1 is essential for gastric cancer progression through AKT/mTOR signaling pathway activation.
- Clinical and prognostic features of E-cadherin in adenocarcinoma of the esophagogastric junction patients.
- Potential Effects of FGFR4 in the Helicobacter pylori-Induced Inflammatory Carcinoma Transformation.
- STAT5A modulates gastric cancer progression via upregulation of CD44.
- Knockdown circZNF131 Inhibits Cell Progression and Glycolysis in Gastric Cancer Through miR-186-5p/PFKFB2 Axis.
- Relationship between glutathione S-transferase M1 gene polymorphism and gastric cancer.
- Reciprocal Expression of Differentiated Embryonic Chondrocyte Expressed Genes Result in Functional Antagonism in Gastric Cancer.
- Clinicopathological Significance of STAT3 and p-STAT3 among 91 Patients with Adenocarcinoma of the Esophagogastric Junction.
- DEC1 promotes progression of Helicobacter pylori-positive gastric cancer by regulating Akt/NF-κB pathway.
- Effect of LAMA4 on Prognosis and Its Correlation with Immune Infiltration in Gastric Cancer.
- Long noncoding RNA NR2F1-AS1 plays a carcinogenic role in gastric cancer by recruiting transcriptional factor SPI1 to upregulate ST8SIA1 expression.
- Andrographolide Induces Apoptosis in Gastric Cancer Cells through Reactivation of p53 and Inhibition of Mdm-2.
- LncPSCA in the 8q24.3 risk locus drives gastric cancer through destabilizing DDX5.
它在 ClinicalTrials.gov 上的全部试验(任何状态)13
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
- A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- Postoperative Adjuvant Therapy for Stage II-III Gastric Cancer
- Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma
- Minimal Residual Disease-guided Adjuvant Therapy for Gastric Cancer
- First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer
- Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
- PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
- A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.
- A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
- Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
癌症
肺癌
Lung cancer2021–2025 年中国大陆作者发表的 23,356 篇肺癌 PubMed 英文论文中,这家医院牵头了 59 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
济南有 9 家医院列在肺癌下全国有 251 家医院列在肺癌下
这家医院参与的开放试验 16
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- 分期
- III期
- 开始
- 2026-01
- 发布
- 登记号
- NCT07222566
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 36 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、台州、合肥、太原、广州、成都、扬州、新乡、杭州、武汉、江门、洛阳、济南、温州、福州、襄阳、郑州、重庆、长春、长沙
- 正在招募RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
- 分期
- III期
- 开始
- 2026-04
- 发布
- 登记号
- NCT07416474
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 66 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、太原、安阳、广州、徐州、成都、新乡、昆明、杭州、桂林、武汉、江门、沈阳、洛阳、济南、深圳、温州、烟台、珠海、石家庄、福州、苏州、襄阳、郑州、重庆、银川、长春、长沙、青岛
- 正在招募Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
- 分期
- II/III期
- 开始
- 2025-01
- 发布
- 登记号
- NCT06712316
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、北京、台州、扬州、杭州、武汉、汕头、济南、石家庄、苏州、蚌埠、重庆、长春、长沙
- 正在招募Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- 分期
- III期
- 开始
- 2025-02
- 发布
- 登记号
- NCT06712355
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、临沂、北京、南昌、台州、合肥、哈尔滨、太原、广州、扬州、新乡、杭州、武汉、汕头、济南、温州、石家庄、福州、苏州、蚌埠、襄阳、郑州、重庆、长春
- 正在招募This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- 分期
- III期
- 开始
- 2025-07
- 发布
- 登记号
- NCT06758401
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 28 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、台州、合肥、哈尔滨、天津、常州、广州、徐州、成都、杭州、武汉、洛阳、济南、温州、福州、西安、郑州、长沙
- 正在招募Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- 分期
- III期
- 开始
- 2025-03
- 发布
- 登记号
- NCT06890598
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 32 家列出的医院为研究中心上海、佛山、北京、南宁、台州、哈尔滨、天津、安阳、广州、成都、杭州、武汉、汕头、洛阳、济南、深圳、苏州、西安、重庆、长沙
- 正在招募A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
- 分期
- I/II期
- 开始
- 2025-05
- 发布
- 登记号
- NCT06892548
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 25 家列出的医院为研究中心临沂、北京、南京、南宁、南昌、厦门、合肥、宜昌、广州、徐州、成都、新乡、杭州、济南、福州、襄阳、西安、郑州、长春
- 正在招募A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
- 分期
- II期
- 开始
- 2025-06
- 发布
- 登记号
- NCT06962865
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 23 家列出的医院为研究中心临沂、北京、哈尔滨、天津、太原、广州、成都、昆明、杭州、桂林、武汉、济南、温州、烟台、石家庄、福州、襄阳、郑州、重庆、长春、长沙
- 正在招募A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
- 分期
- I/II期
- 开始
- 2025-09
- 发布
- 登记号
- NCT07111520
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 22 家列出的医院为研究中心上海、南昌、合肥、天津、广州、徐州、成都、扬州、新乡、武汉、济南、石家庄、福州、苏州、襄阳、重庆、长春、青岛
- 正在招募A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- 分期
- III期
- 开始
- 2025-09
- 发布
- 登记号
- NCT07144280
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、北京、南京、南宁、南昌、台州、合肥、哈尔滨、常州、广州、徐州、成都、杭州、武汉、济南、福州、西安、郑州、重庆、长沙
- 正在招募A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
- 分期
- III期
- 开始
- 2025-12
- 发布
- 登记号
- NCT07182682
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 47 家列出的医院为研究中心上海、北京、南京、南宁、台州、合肥、哈尔滨、天津、太原、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、福州、西安、郑州、长春、长沙
- 正在招募Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- 分期
- III期
- 开始
- 2025-12
- 发布
- 登记号
- NCT07185997
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 45 家列出的医院为研究中心上海、临沂、佛山、北京、南京、南宁、南昌、南通、合肥、呼和浩特、哈尔滨、大连、天津、太原、广州、成都、新乡、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、潍坊、石家庄、福州、郑州、重庆、长沙、青岛
- 正在招募A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
- 分期
- II期
- 开始
- 2023-12
- 发布
- 登记号
- NCT06010329
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、北京、南京、南昌、哈尔滨、广州、成都、杭州、武汉、济南、郑州
- 正在招募A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- 分期
- III期
- 开始
- 2023-12
- 发布
- 登记号
- NCT06119581
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 28 家列出的医院为研究中心上海、临沂、乌鲁木齐、北京、南昌、台州、哈尔滨、天津、宜昌、常州、广州、成都、杭州、武汉、济南、海口、湛江、福州、襄阳、西安、长沙
- 正在招募Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- 分期
- III期
- 开始
- 2023-12
- 发布
- 登记号
- NCT06170788
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南昌、厦门、台州、合肥、哈尔滨、广州、徐州、成都、无锡、杭州、武汉、济南、湛江、石家庄、福州、襄阳、郑州、长沙
- 正在招募A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- 分期
- III期
- 开始
- 2022-03
- 发布
- 登记号
- NCT04928846
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、临沂、乌鲁木齐、北京、南京、南宁、南昌、南通、厦门、台州、合肥、呼和浩特、哈尔滨、大连、天津、太原、广州、成都、昆明、杭州、武汉、汕头、沈阳、济南、湛江、石家庄、福州、西安、郑州、重庆、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文59
- The α5-nAChR/GINS4 axis contributed to nicotine-promoted lung adenocarcinoma progression.
- Novel Evolutionarily Conserved Oncogene COA4 is Driven by KRAS Mutant and Promotes Cancer Metastasis Through Dual Mitochondrial Metabolism-Dependent and -Independent Mechanisms.
- Clinical evaluation of a novel-developed clone 3E2 for the detection of PD-L1 expression status in lung adenocarcinoma.
- Investigation into the Spatial Heterogeneity of Lung Composite Large-Cell Neuroendocrine Carcinoma Spatial Transcriptomic Analysis of Combined Large-Cell Neuroendocrine Carcinoma.
- The diagnostic value of serum exosomal SNORD116 and SNORA21 for NSCLC patients.
- Impact of MEK inhibition on T-cell infiltration and function after radiotherapy in KRAS-mutant lung cancer.
- The impact of comorbid COPD on survival outcomes in lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
- Severe thyroiditis induced by sintilimab monotherapy in a patient with non-small cell lung cancer: a case report and literature review.
- ZEB1 Contributes to Drug Resistance Through Canonical Wnt Signaling in Lung Cancer.
- Immunoglobulin-like transcript 5 polarizes M2-like tumor-associated macrophages for immunosuppression in non-small cell lung cancer.
- Simultaneous treatment of pulmonary ground-glass opacity nodules with microwave ablation and coaxial puncture biopsy.
- Clinical application of microwave ablation combined with coaxial needle biopsy using different sequences for treating lung nodules suggestive of malignancy.
- Resolving the spatial and cellular architecture of intra-tumor heterogeneity by multi-region dissection of lung adenocarcinoma.
- Correlation of Peripheral Blood CD4/CD8 Ratio with Efficacy and Prognosis in Patients with Non-Small Cell Lung Cancer Receiving PD-1/PD-L1 Inhibitors.
- Prognostic Significance of CD4+ Tumour Infiltrating Lymphocytes in Patients with Non-Small Cell Lung Cancer Receiving PD-1/PD-L1 Inhibitors Therapy.
- The role of glutathione peroxidase 4 in the progression, drug resistance, and targeted therapy of non-small cell lung cancer.
- Lung Cancer with Axillary Lymph Node Involvement: A Case Report and Literature Review on a Rare Mode of Metastasis.
- Feasibility of an artificial intelligence system for tumor response evaluation.
- Nicotine promotes M2 macrophage polarization through α5-nAChR/SOX2/CSF-1 axis in lung adenocarcinoma.
- Dual-Phase Enhanced CT-Derived Radiomics Nomogram for Progression-Free Survival Prediction in Stage IV Lung Adenocarcinoma.
- Evaluation of an Algorithm for the Segmentation of Lung Nodules in Computerized Tomography Images based on the Automatic Location of a Threshold.
- The innovative checkpoint inhibitors of lung adenocarcinoma, cg09897064 methylation and ZBP1 expression reduction, have implications for macrophage polarization and tumor growth in lung cancer.
- PLEK2 mediates metastasis and invasion via α5-nAChR activation in nicotine-induced lung adenocarcinoma.
- CALU promotes lung adenocarcinoma progression by enhancing cell proliferation, migration and invasion.
- Whole-exome sequencing explored mechanism of selpercatinib resistance in RET-rearranged lung adenocarcinoma transformation into small-cell lung cancer: a case report.
- A retrospective study on the efficacy and safety of Endostar with chemotherapy in EGFR-TKI-resistant NSCLC.
- Multi-classification model incorporating radiomics and clinic-radiological features for predicting invasiveness and differentiation of pulmonary adenocarcinoma nodules.
- α5-nAChR/STAT3/CD47 axis contributed to nicotine-related lung adenocarcinoma progression and immune escape.
- Acetylcholine promotes chronic stress-induced lung adenocarcinoma progression via α5-nAChR/FHIT pathway.
- GRIN2D knockdown suppresses the progression of lung adenocarcinoma by regulating the E2F signalling pathway.
- Association between CD8+ tumor-infiltrating lymphocytes and prognosis of non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis.
- Radiomics nomogram for the prediction of Ki-67 index in advanced non-small cell lung cancer based on dual-phase enhanced computed tomography.
- ILT4 reprograms glucose metabolism to promote tumor progression in triple-negative breast cancer.
- Clinical Study of Artificial Intelligence in Imaging Diagnosis of False Positive Lesions of Pulmonary Nodules.
- Heat shock protein B7 (HSPB7) inhibits lung adenocarcinoma progression by inhibiting glycolysis.
- Role of the cGAS-STING pathway in radiotherapy for non-small cell lung cancer.
- Radiation combined with KRAS-MEK inhibitors enhances anticancer immunity in KRAS-mutated tumor models.
- Comparison of the BOPPPS model and traditional instructional approaches in thoracic surgery education.
- α5-nAChR associated with Ly6E modulates cell migration via TGF-β1/Smad signaling in non-small cell lung cancer.
- Alpha5 nicotinic acetylcholine receptor mediated immune escape of lung adenocarcinoma via STAT3/Jab1-PD-L1 signalling.
- Effect of Food Intake on Pharmacokinetics of Oral Almonertinib: A Randomized Crossover Trial in Healthy Chinese Participants.
- Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.
- The α5-nAChR/PD-L1 axis facilitates lung adenocarcinoma cell migration and invasion.
- Establishment and Validation of a Novel Nomogram for Predicting Distant Metastasis in Patients with Invasive Lung Adenocarcinoma.
- Research progress on the occurrence and therapeutic mechanism of ferroptosis in NSCLC.
- The role of α5-nicotinic acetylcholine receptor/NLRP3 signaling pathway in lung adenocarcinoma cell proliferation and migration.
- Immune subgroup analysis for non-small cell lung cancer may be a good choice for evaluating therapeutic efficacy and prognosis.
- Artificial pneumothorax improves radiofrequency ablation of pulmonary metastases of hepatocellular carcinoma close to mediastinum.
- Assessment of safety margin after microwave ablation of stage I NSCLC with three-dimensional reconstruction technique using CT imaging.
- Prognostic value of neuron-specific enolase in patients with advanced and metastatic non-neuroendocrine non-small cell lung cancer.
- Clinical characteristics and outcomes of Chinese patients with KRAS-mutant non-small cell lung cancer after chemotherapy.
- ILT3 promotes tumor cell motility and angiogenesis in non-small cell lung cancer.
- Potential chemotherapeutic effect of betalain against human non-small cell lung cancer through PI3K/Akt/mTOR signaling pathway.
- Suppression of HELLS by miR-451a represses mTOR pathway to hinder aggressiveness of SCLC.
- Insufficient ablation promotes the metastasis of residual non-small cell lung cancer (NSCLC) cells via upregulating carboxypeptidase A4.
- α5-nAChR and survivin: Two potential biological targets in lung adenocarcinoma.
- Correlation between Circulating Tumor Cells and Plasma D-dimer and Clinicopathological Characteristics of Patients with Non-small Cell Lung Cancer.
- Inhibition Sequence of miR-205 Hinders the Cell Proliferation and Migration of Lung Cancer Cells by Regulating PETN-Mediated PI3K/AKT Signal Pathway.
- ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
它在 ClinicalTrials.gov 上的全部试验(任何状态)49
- Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
- A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
- This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
- Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
- Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
- A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
- A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
- Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC
- A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
- Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
- A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
- A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer
- ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
- A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC
- Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
- Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
- Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
- A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
- Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)
- A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
- A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC
- A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC
- Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
- Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer
- A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
- A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
- Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
- A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer
- Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
- A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC
- A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer
- A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer
- Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)
- Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
- A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients
- Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
- Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer
癌症
乳腺癌
Breast cancer2021–2025 年中国大陆作者发表的 16,974 篇乳腺癌 PubMed 英文论文中,这家医院牵头了 21 篇,占 0.1%。
济南有 8 家医院列在乳腺癌下全国有 219 家医院列在乳腺癌下
这家医院参与的开放试验 7
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 邀请入组Concept-verification Clinical Trial on the Inhibition of Breast Cancer Lung Metastasis Progression by Hyperbaric Oxygen
- 分期
- 不分期
- 开始
- 2025-11
- 发布
- 登记号
- NCT07514728
年龄 18 岁 至 75 岁;仅女性(登记的条件)
- 正在招募A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer
- 分期
- I期
- 开始
- 2025-03
- 发布
- 登记号
- NCT06738966
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 2 家列出的医院为研究中心济南、长春
- 正在招募A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- 分期
- III期
- 开始
- 2025-03
- 发布
- 登记号
- NCT06841354
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 21 家列出的医院为研究中心乌鲁木齐、南京、南宁、厦门、台州、太原、广州、徐州、成都、杭州、武汉、济南、蚌埠、襄阳、西安、郑州、重庆、长春、长沙
- 正在招募A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- 分期
- III期
- 开始
- 2025-06
- 发布
- 登记号
- NCT06966700
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 21 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南宁、厦门、合肥、哈尔滨、杭州、武汉、济南、西安、郑州、长春、长沙
- 正在招募A Study of YL202 in Selected Patients With Advanced Solid Tumors
- 分期
- II期
- 开始
- 2023-12
- 发布
- 登记号
- NCT06107686
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 45 家列出的医院为研究中心上海、乌鲁木齐、北京、南宁、南昌、台州、合肥、哈尔滨、太原、广州、徐州、成都、杭州、桂林、梅州、武汉、汕头、沈阳、济南、潍坊、苏州、襄阳、西安、郑州、重庆、长春、长沙、青岛
- 正在招募A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid Tumors
- 分期
- I期
- 开始
- 2022-08
- 发布
- 登记号
- NCT05461768
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 5 家列出的医院为研究中心广州、武汉、济南、福州、郑州
- 正在招募A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
- 分期
- III期
- 开始
- 2022-01
- 发布
- 登记号
- NCT05851014
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 32 家列出的医院为研究中心上海、临沂、佛山、南京、南宁、南昌、合肥、宁波、广州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、银川、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文21
- Efficacy and safety of first-line CDK4/6 inhibitors plus AI therapy for patients with HR +/HER2- advanced breast cancer: a network meta-analysis.
- TUFT1 regulates cancer progression by suppressing centrosome amplification and mitotic spindle multipolarity.
- Investigating the molecular mechanisms of phytochemicals targeting Ras-related C3 botulinum toxin substrate 1 (Rac1) to inhibit breast cancer metastasis via endoplasmic reticulum stress and Wnt-PCP signaling pathway.
- Value of postmastectomy radiotherapy on overall survival in stage II-III node-negative patients following neoadjuvant therapy: A surveillance, epidemiology, and end results-based population study.
- MRI Radiomics-Based Prediction of Occult Sentinel Lymph Node Metastasis and D2-40 Expression in Breast Cancer.
- Prediction of lymphovascular invasion in invasive breast cancer based on clinical-MRI radiomics features.
- Themis: advancing precision oncology through comprehensive molecular subtyping and optimization.
- Study on the differential diagnosis of benign and malignant breast lesions using a deep learning model based on multimodal images.
- Application of rapid rehabilitation surgical concepts in the care of patients with modified radical breast cancer in the perioperative period.
- LINC02535 + miR-30a-5p combination enhances proliferation and inhibits apoptosis in metastatic breast Cancer cells.
- Identifying miRNA biomarkers for breast cancer and ovarian cancer: a text mining perspective.
- CXCL9 influences the tumor immune microenvironment by stimulating JAK/STAT pathway in triple-negative breast cancer.
- The Role of Mesenchymal Stem Cells in Modulating the Breast Cancer Microenvironment.
- Small Bowel Metastases From Malignant Phyllodes Breast Tumor Detected by 18 F-FDG PET/CT.
- SGK1 is involved in doxorubicin-induced chronic cardiotoxicity and dysfunction through activation of the NFκB pathway.
- ILT4 reprograms glucose metabolism to promote tumor progression in triple-negative breast cancer.
- The effects of qigong intervention based on the Internet on quality of life and physical fitness in Chinese postoperative breast cancer patients: a protocol of randomized controlled trial.
- The Significance of Tumor Microenvironment Score for Breast Cancer Patients.
- Long non-coding RNA PVT1 facilitates cell migration and invasion by regulating miR-148a-3p and ROCK1 in breast cancer.
- Clinical Value of Total Intravenous Anesthesia with Sufentanil and Propofol in Radical Mastectomy.
- Application of fluorescein combined with methylene blue in sentinel lymph node biopsy of breast cancer.
它在 ClinicalTrials.gov 上的全部试验(任何状态)18
- Concept-verification Clinical Trial on the Inhibition of Breast Cancer Lung Metastasis Progression by Hyperbaric Oxygen
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- A Study of YL202 in Selected Patients With Advanced Solid Tumors
- A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
- A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid Tumors
- Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
- A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
- A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
- A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
- A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
- GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer
- A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer
- A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
- Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
- Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer
- Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer
癌症
视网膜母细胞瘤
Retinoblastoma2021–2025 年没有牵头视网膜母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
济南有 8 家医院列在视网膜母细胞瘤下全国有 176 家医院列在视网膜母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
济南有 18 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文6
- Exosomal Gene Biomarkers in Osteosarcoma: Mifepristone as a Targeted Therapeutic Revealed by Multi-Omics Analysis.
- The osteosarcoma immune microenvironment in progression: PLEK as a prognostic biomarker and therapeutic target.
- Emerging immunotherapies in osteosarcoma: from checkpoint blockade to cellular therapies.
- m6A-modified circARHGAP12 promotes the aerobic glycolysis of doxorubicin-resistance osteosarcoma by targeting c-Myc.
- DEPDC1 as a crucial factor in the progression of human osteosarcoma.
- TRIM59 promotes osteosarcoma progression via activation of STAT3.
早期论文(2016–2020 年)5
- MiR-196a promoted cell migration, invasion and the epithelial-mesenchymal transition by targeting HOXA5 in osteosarcoma.
- Silencing of long-non-coding RNA ANCR suppresses the migration and invasion of osteosarcoma cells by activating the p38MAPK signalling pathway.
- Downregulation of UBE2T can enhance the radiosensitivity of osteosarcoma in vitro and in vivo.
- Combination of anginex gene therapy and radiation decelerates the growth and pulmonary metastasis of human osteosarcoma xenografts.
- β-Aescin shows potent antiproliferative activity in osteosarcoma cells by inducing autophagy, ROS generation and mitochondrial membrane potential loss.
癌症
胃肠道间质瘤
Gastrointestinal stromal tumour2021–2025 年没有牵头胃肠道间质瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
济南有 4 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。
血液疾病
血友病 A
Haemophilia A2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
济南有 3 家医院列在血友病 A下全国有 132 家医院列在血友病 A下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
- 分期
- III期
- 开始
- 2025-03
- 发布
- 登记号
- NCT06833983
年龄 18 岁 至 65 岁;仅男性(登记的条件)
牵头方不是列出的医院;另有 13 家列出的医院为研究中心兰州、北京、南京、南昌、合肥、唐山、天津、广州、昆明、武汉、济南、郑州、长沙
- 正在招募An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
- 分期
- I/II期
- 开始
- 2024-05
- 发布
- 登记号
- NCT07644832
年龄 18 岁 至 65 岁(登记的条件)
牵头方不是列出的医院;另有 7 家列出的医院为研究中心兰州、合肥、太原、济南、西安、郑州、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)14
- To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
- An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
- Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.
- Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment
- Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products
- A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A
- A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
- Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
- Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)
- Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A
- A Study to Evaluate the Pharmacokinetics,Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
- A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors
- An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.
- A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
其他疾病
冠心病
Coronary heart disease2021–2025 年中国大陆作者发表的 5,119 篇冠心病 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
济南有 6 家医院列在冠心病下全国有 231 家医院列在冠心病下
截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的冠心病开放试验。
这些数字背后的记录
牵头的论文6
- Reduced contrast agent volume using a heart-rate dependent and free-breathing scanning protocol in coronary computed tomography angiography (CTA) for patients with chronic obstructive pulmonary disease (COPD).
- The Predictive Value of Multiparameter Characteristics of Coronary Computed Tomography Angiography for Coronary Stent Implantation.
- The effect of gum consumption on blood pressure as a risk factor for coronary heart disease: A meta-analysis of controlled trials.
- Nicorandil Decreases Renal Injury in Patients With Coronary Heart Disease Complicated With Type I Cardiorenal Syndrome.
- Application Effect of Meticulous Nursing on Community Elderly Patients with Coronary Heart Disease under the Background of Medical Treatment Partnerships.
- Influence of sex and menopausal status on the relationship between metabolic syndrome and coronary artery calcification: a Chinese community-based cross-sectional study.
其他疾病
抗 NMDA 受体脑炎
Anti-NMDA receptor encephalitis2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.8%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
济南有 5 家医院列在抗 NMDA 受体脑炎下全国有 124 家医院列在抗 NMDA 受体脑炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。
其他疾病
家族性腺瘤性息肉病
Familial adenomatous polyposis2021–2025 年没有牵头家族性腺瘤性息肉病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
济南有 2 家医院列在家族性腺瘤性息肉病下全国有 74 家医院列在家族性腺瘤性息肉病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。
联系这家医院
出示给工作人员或司机的院名卡
山东第一医科大学附属中心医院(济南市中心医院)
Central Hospital Affiliated to Shandong First Medical University
济南
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药
下一步建议
这些数字从哪里来
论文
2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义
试验
ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。